Your browser doesn't support javascript.
loading
Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy.
Gao, Ai; Guan, Shasha; Sun, Yinjuan; Wang, Lingling; Meng, Fanlu; Liu, Xia; Gu, Liyan; Li, Guo; Zhong, Diansheng; Zhang, Linlin.
Afiliación
  • Gao A; Department of Medical Oncology, Tianjin Medical University General Hospital, No.154, Anshan Dao, Heping District, Tianjin, 300052, China.
  • Guan S; Department of Medical Oncology, Tianjin Medical University General Hospital, No.154, Anshan Dao, Heping District, Tianjin, 300052, China.
  • Sun Y; Department of Medical Oncology, Tianjin Medical University General Hospital, No.154, Anshan Dao, Heping District, Tianjin, 300052, China.
  • Wang L; Department of Medical Oncology, Tianjin Medical University General Hospital, No.154, Anshan Dao, Heping District, Tianjin, 300052, China.
  • Meng F; Department of Medical Oncology, Tianjin Medical University General Hospital, No.154, Anshan Dao, Heping District, Tianjin, 300052, China.
  • Liu X; Department of Medical Oncology, Tianjin Medical University General Hospital, No.154, Anshan Dao, Heping District, Tianjin, 300052, China.
  • Gu L; Department of Medical Oncology, Tianjin Medical University General Hospital, No.154, Anshan Dao, Heping District, Tianjin, 300052, China.
  • Li G; Department of Medical Oncology, Tianjin Medical University General Hospital, No.154, Anshan Dao, Heping District, Tianjin, 300052, China.
  • Zhong D; Department of Medical Oncology, Tianjin Medical University General Hospital, No.154, Anshan Dao, Heping District, Tianjin, 300052, China. hongdsh@hotmail.com.
  • Zhang L; Department of Medical Oncology, Tianjin Medical University General Hospital, No.154, Anshan Dao, Heping District, Tianjin, 300052, China. zllcaroline@tmu.edu.cn.
BMC Cancer ; 23(1): 609, 2023 Jul 01.
Article en En | MEDLINE | ID: mdl-37393241
BACKGROUND: Even though chemotherapy-induced nausea and vomiting (CINV) can be well controlled in the acute phase, the incidence of delayed CINV remains high. In this study, we intend to investigate whether prolonged use of NK-1 receptor antagonist (RA) in addition to 5-HT3 RA and dexamethasone (DEX) was more effective in preventing delayed CINV. METHODS: This randomised, open-label, controlled study was designed to compare the efficacy and safety of fosaprepitant 150 mg given on days 1,3 (prolonged group) versus on day 1 (regular group) in patients receiving highly emetogenic chemotherapy (HEC). All patients also treated with palonosetron on day 1 and DEX on days 1-3. The primary endpoint was the incidence of delayed nausea and vomiting. The second endpoint was AEs. All the above endpoints were defined according to CTCAE 5.0. RESULTS: Seventy-seven patients were randomly assigned to prolonged group and seventy-nine to regular group. Prolonged group demonstrated superiority in controlling delayed CINV to regular group, with statistically significant lower incidence of nausea (6.17% vs 12.66%, P = 0.0056), and slightly lower incidence of grade 1 vomiting (1.62% vs 3.80%, P = 0.0953) in the delayed phase. In addition, prolonged use of fosaprepitant was safe. No significant difference was found between the two groups regarding constipation, diarrhea, hiccough, fatigue, palpitation and headache in delayed phase. CONCLUSIONS: Prolonged use of fosaprepitant can effectively and safely prevent delayed CINV in patients receiving HEC.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Náusea / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Náusea / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido